Quantcast
Home > Quotes > GERN
GERN

Geron Corporation Common Stock (GERN) Quote & Summary Data

$1.535
*  
0.025
1.6%
Get GERN Alerts
*Delayed - data as of Nov. 14, 2018 14:37 ET  -  Find a broker to begin trading GERN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    GERN Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 1.53 / $ 1.54
1 Year Target
1.5
Today's High / Low
$ 1.60 / $ 1.49
Share Volume
2,070,920
50 Day Avg. Daily Volume
8,860,670
Previous Close
$ 1.56
52 Week High / Low
$ 6.99 / $ 1.46
Market Cap
286,044,281
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.16
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.12

Intraday Chart

Shares Traded

Share Volume:
2,070,920
50 Day Avg. Daily Volume:
8,860,670

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.16

Trading Range

The current last sale of $1.535 is 5.14% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.60 $ 6.99
 Low: $ 1.49 $ 1.46

Company Description (as filed with the SEC)

We are a biopharmaceutical company that currently supports the clinical stage development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies, by Janssen Biotech, Inc., or Janssen. Early clinical data in essential thrombocythemia, or ET, myelofibrosis, or MF, and myelodysplastic syndromes, or MDS, suggest imetelstat may have disease¬≠modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases. On November 13, 2014, we entered into a collaboration and license agreement, or the Collaboration Agreement, pursuant to which we granted Janssen the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses. The Collaboration Agreement became effective on December 15, 2014, and we received $35 million from Janssen as an upfront payment.  ... More ...  


Risk Grade

Where does GERN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.60
Open Date:
Nov. 14, 2018
Close Price:
$ 1.56
Close Date:
Nov. 13, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x